Afatinib is the first ErbB family approved blocking agent, used to treat with EGFR activatingmutations in patients with non small cell lung cancer; dacomitinib are in the later stages of clinicaldevelopment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.